Pakistan: 40 Life-Saving Medicines Unavailable Due to Price Approval Delays
Approximately 40 newly registered, life-saving medicines remain inaccessible to patients in Pakistan because the federal government has not yet approved their prices. This delay forces individuals suffering from critical illnesses such as cancer, diabetes, hemophilia, and Parkinson's disease to resort to expensive, potentially unsafe smuggled or unregistered alternatives. Officials and market sources indicate that the hold-up in price notifications is preventing the legal marketing of essential treatments, including advanced cancer therapies like Keytruda and Nivolumab, as well as insulins, autoimmune disease medications, and treatments for severe infections.
The Drug Regulatory Authority of Pakistan (Drap) has completed the registration process for these medicines, with price recommendations finalized by the Drug Pricing Committee between December 2024 and June 2025. These recommendations were endorsed by the Drap Policy Board and forwarded to the federal government for final approval, which is still pending. While prices for an earlier batch of 35 medicines have been approved, the remaining 40 await clearance from the Cabinet Committee and the federal cabinet. Industry representatives, including the Pakistan Chemists and Druggists Association and the Pakistan Pharmaceutical Manufacturers Association, have voiced concerns, highlighting the risks associated with unregulated medicines and urging the government to expedite the approval process to ensure timely patient access to innovative therapies.
The delay in approving prices for essential medicines in Pakistan highlights a critical governance challenge where regulatory registration is outpaced by administrative price control mechanisms. This situation creates a market vacuum, incentivizing the proliferation of informal, unregulated supply chains that compromise patient safety and treatment efficacy. The systemic contradiction lies in the state's dual role: facilitating drug registration while simultaneously obstructing market entry through bureaucratic inertia. Looking ahead, such delays could deter pharmaceutical innovation and investment, particularly for treatments targeting less common but severe conditions, as companies face unpredictable market access timelines. Future policy frameworks may need to integrate price approval more seamlessly with regulatory registration, potentially through tiered approval processes or independent pricing review bodies, to ensure timely patient access to critical medical advancements.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.